Notably, the MEK1/2 inhibitor Trametinib was shown to be able to induce retroelement activation and IFNB1 gene expression in pancreatic cancer cells (Cortesi et al, 2024). The gene discussed is MAP2K1; the disease is pancreatic neoplasm.